Evidence Grade A — Regulatory approved. 2770 published studies. 327 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Exenatide (sold as Byetta and Bydureon) was the first GLP-1 medication to reach the market and is based on a naturally occurring protein discovered in Gila monster saliva. Approved for type 2 diabetes, it mimics the gut hormone GLP-1 to help control blood sugar and promote modest weight loss. Available as a twice-daily or once-weekly injection.
Exenatide is also known by these brand and alternate names:
2,770 published studies: 1877 human, 339 animal, 200 in-vitro, 837 reviews
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg.
The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Exenatide works by activating the same GLP-1 receptor as your body's natural gut hormone, but it resists the enzyme that normally breaks GLP-1 down within minutes. This means its effects last much longer. It stimulates insulin release when blood sugar is high, reduces the hormone that raises blood sugar, slows digestion, and curbs appetite. Uniquely, exenatide is derived from a protein found in Gila monster venom that naturally has these GLP-1-like properties, which scientists were able to develop into a diabetes treatment.
Exenatide holds an important place in medical history as the drug that validated the GLP-1 receptor as a treatment target, launching what became one of the most successful drug classes in modern medicine. Clinical trials showed blood sugar reductions (HbA1c) of 1.6-1.9% and modest weight loss of 2-4 kg. However, the large cardiovascular outcomes trial (EXSCEL, involving over 14,700 patients) narrowly missed showing a heart benefit — a result that positioned exenatide behind liraglutide, semaglutide, and dulaglutide in treatment guidelines. The once-weekly formulation (Bydureon) was discontinued in the US in January 2024 due to declining market share as newer, more effective GLP-1 treatments took over. Interestingly, exenatide is being studied for potential neuroprotective effects in Parkinson's disease, with early trial results showing encouraging signals.
PeptideTrace tracks 327 registered clinical trials for Exenatide sourced from ClinicalTrials.gov.
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Exenatide For Reducing the Reinforcing Effects of Cocaine
FDA ORIG 1
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 2
FDA SUPPL 7
FDA SUPPL 12
FDA SUPPL 10
FDA SUPPL 18
FDA SUPPL 22
FDA SUPPL 25
FDA SUPPL 17
FDA SUPPL 9
FDA SUPPL 11
FDA SUPPL 26
FDA SUPPL 28
Health Canada Market Authorisation
EMA Marketing Authorisation
FDA SUPPL 31
FDA SUPPL 30
FDA SUPPL 29
FDA SUPPL 34
FDA SUPPL 35
FDA SUPPL 38
FDA SUPPL 37
FDA SUPPL 39
FDA SUPPL 36
FDA SUPPL 40
FDA SUPPL 41
FDA SUPPL 43
FDA SUPPL 44
FDA SUPPL 45
FDA SUPPL 46
FDA SUPPL 47
FDA SUPPL 48
FDA SUPPL 49
FDA ORIG 1
FDA SUPPL 50
FDA SUPPL 51
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). It shares only 53% sequence homology with human GLP-1 and is classified as an incretin mimetic rather than a GLP-1 analogue. Its non-mammalian origin provides inherent resistance to DPP-4 degradation without requiring structural modification.
Exenatide activates the GLP-1 receptor via the canonical Gs/cAMP pathway, producing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. Unlike human GLP-1 analogues (liraglutide, semaglutide), exenatide lacks acyl chain modifications for albumin binding. The immediate-release formulation (Byetta) has a half-life of approximately 2.4 hours, while the extended-release formulation (Bydureon) uses PLGA microsphere technology for sustained release over 7 days.
Exenatide is marketed as Byetta (twice-daily SC injection, approved April 28, 2005—the first GLP-1 receptor agonist) and Bydureon/Bydureon BCise (once-weekly extended-release, approved January 27, 2012). Clinical trials showed HbA1c reductions of 1.6–1.9% with Bydureon and weight loss of 2.3–3.7 kg. The EXSCEL cardiovascular outcomes trial (N=14,752; median 3.2 years) demonstrated noninferiority versus placebo for MACE but did not achieve superiority (HR 0.91; 95% CI 0.83–1.00; P=0.06). In head-to-head comparison (SUSTAIN 3), semaglutide 1.0 mg was superior to exenatide 2 mg weekly for both HbA1c (−1.5% vs −0.9%) and weight loss.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Evidence Reviews
Timelines
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
